Interpace Biosciences Inc (IDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Sales | 305,205 | 345,797 | 344,530 | 307,875 | 696,583 |
| Cost of Goods | 252,803 | 253,164 | 255,449 | 278,002 | 560,800 |
| Gross Profit | 52,402 | 92,633 | 89,081 | 29,873 | 135,783 |
| Operating Expenses | 72,045 | 58,718 | 69,940 | 80,050 | 123,878 |
| Operating Income | -18,840 | 34,079 | 19,590 | -50,175 | 12,705 |
| Other Income | 7,634 | 779 | 1,073 | 1,967 | 2,275 |
| Pre-tax Income | -11,206 | 34,858 | 20,663 | -48,208 | 14,980 |
| Income Tax | 201 | 14,423 | 8,405 | -17,447 | 8,626 |
| Net Income Continuous | -11,407 | 20,435 | 12,258 | -30,761 | 6,354 |
| Net Income Discontinuous | -8,047 | 697 | N/A | N/A | N/A |
| Net Income | $-19,454 | $21,132 | $12,258 | $-30,761 | $6,354 |
| EPS Basic Total Ops | -137.00 | 145.00 | 86.00 | -219.00 | 46.00 |
| EPS Basic Continuous Ops | -80.00 | 140.00 | 86.14 | -219.20 | 45.76 |
| EPS Basic Discontinuous Ops | -57.00 | 5.00 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -137.00 | 142.00 | 85.00 | -219.00 | 45.00 |
| EPS Diluted Continuous Ops | -80.00 | 137.00 | 84.94 | -219.20 | 45.02 |
| EPS Diluted Discontinuous Ops | -57.00 | 5.00 | N/A | N/A | N/A |
| EBITDA(a) | $-13,020 | $39,995 | $25,833 | $-42,801 | $17,699 |